Résumé
A reflection on the referencing of biosimilar Infliximab in our establishment has been conducted by the drug committee since 2015. Methods. Since 2000, the Georges-Pompidou European Hospital supports a cohort of 2,365 patients with Crohn's disease or ulcerative colitis in the gastroenterology department. As with any drug proposed to the drug committee, an evaluation of objective criteria, including an analysis of therapeutic indications, tolerance, use with risk factors and alternatives within the therapeutic class, is carried out. Results. Referencing, prescription procedures, communication to teams and patients, and follow-up of biosimilar Infliximab were discussed during two drug committee meetings in October 2015 and October 2016. The committee took the decision to switch from Remicade® to Infliximab biosimilar all patients under Remicade® after informing the patient with an explaining letter. Paramedical teams were informed of these prescription changes and their modalities. Conclusion: Following the referencing of new biosimilars to AP-HP drug committed and drugs markets changing every three years, several specialties of original or biosimilar drugs will be available at hospital. To overcome market changes, drugs are prescribed in nonproprietary name and doctors have decided to present the drugs with this name to patient.
Titre traduit de la contribution | The use of the first biosimilar monoclonal antibody (infliximab): Feedback |
---|---|
langue originale | Français |
Pages (de - à) | 15-18 |
Nombre de pages | 4 |
journal | Journal de Pharmacie Clinique |
Volume | 37 |
Les DOIs | |
état | Publié - 1 mars 2018 |
Modification externe | Oui |
mots-clés
- Biosimilar pharmaceuticals
- Hospital medication referencing
- Infliximab